Compare HYLN & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYLN | BWAY |
|---|---|---|
| Founded | 2018 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.4M | 450.8M |
| IPO Year | 2019 | N/A |
| Metric | HYLN | BWAY |
|---|---|---|
| Price | $1.98 | $13.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $13.25 |
| AVG Volume (30 Days) | ★ 946.6K | 130.3K |
| Earning Date | 05-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,475,000.00 | N/A |
| Revenue This Year | $32.29 | $301.23 |
| Revenue Next Year | $174.03 | $24.33 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | ★ 130.28 | N/A |
| 52 Week Low | $1.11 | $7.84 |
| 52 Week High | $2.56 | $26.63 |
| Indicator | HYLN | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 29.39 |
| Support Level | $1.86 | $11.55 |
| Resistance Level | $2.04 | $17.20 |
| Average True Range (ATR) | 0.13 | 1.05 |
| MACD | -0.00 | -0.64 |
| Stochastic Oscillator | 37.50 | 14.18 |
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.